Ileal perforation in the setting of atezolizumab immunotherapy for advanced bladder cancer.
Can J Urol
; 25(5): 9525-9526, 2018 10.
Article
in En
| MEDLINE
| ID: mdl-30281011
ABSTRACT
Atezolizumab is a promising immunotherapy for advanced urothelial carcinoma. Like other immune checkpoint inhibitors, it can produce rare immune-related adverse events (IRAEs). Here we present the recent case of a patient with metastatic bladder cancer who developed diarrhea and abdominal pain months after beginning atezolizumab therapy. He presented to our institution with an ileal perforation secondary to atezolizumab-induced enterocolitis. After surgical repair, the patient's condition improved, and he was discharged. We discuss the management of atezolizumab-induced enterocolitis, including the importance of early recognition and intervention to prevent more devastating complications.
Search on Google
Database:
MEDLINE
Main subject:
Urinary Bladder Neoplasms
/
Carcinoma, Transitional Cell
/
Enterocolitis
/
Antineoplastic Agents, Immunological
/
Ileal Diseases
/
Intestinal Perforation
/
Antibodies, Monoclonal
Limits:
Aged
/
Humans
/
Male
Language:
En
Year:
2018
Type:
Article